Selective estrogen receptor modulators decrease invasiveness in pituitary adenoma cell lines AtT-20 and TtT/GF by affecting expression of MMP-14 and ADAM12

Zhuo Zhang1,2, Jörg W. Bartsch1, Julia Benzel1,3, Ting Lei2, Christopher Nimsky1 and Benjamin Voellger1

1 Department of Neurosurgery, University Hospital Marburg, Germany
2 Department of Neurosurgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
3 Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany

Open access funding enabled and organized by ProjektDEAL.

Keywords
ADAM proteases; anti-estrogens; invasiveness; matrix metalloproteinases; pituitary adenoma

Correspondence
B. Voellger, Department of Neurosurgery, University Hospital Marburg, Baldingerstr., Marburg 35033, Germany
Tel: +49 6421 58 66447
E-mail: voellger@med.uni-marburg.de

(Received 21 August 2020, revised 25 September 2020, accepted 6 October 2020)

doi:10.1002/2211-5463.12999

Selective estrogen receptor modulators (SERMs) significantly affect survival and invasiveness of rodent pituitary adenoma (PA) cells. The impact of three clinically relevant SERMs (bazedoxifene, clomiphene, raloxifene) on invasiveness and on gene and protein expression of invasion-related proteases [matrix metalloproteinase-14 (MMP-14) and A disintegrin and metalloproteinase-12 (ADAM12)] was analyzed in murine PA cells (AtT-20 and TtT/GF). All SERMs significantly decreased cell invasiveness. Moreover, SERMs significantly decreased expression of ADAM12 mRNA in both cell lines and of MMP-14 mRNA in TtT/GF cells. Invasion rates of AtT-20 and TtT/GF significantly decreased after ADAM12 gene silencing, and the invasion rate of TtT/GF cells significantly decreased after MMP-14 gene silencing. All SERMs affected ADAM12 protein expression in AtT-20 cells whereas bazedoxifene and raloxifene decreased MMP-14 protein expression in TtT/GF cells. We conclude that SERMs attenuate invasiveness of murine PA cells by downregulating expression levels of invasion-related proteases MMP-14 and ADAM12.

Pituitary adenomas (PAs) may exert a mass effect on neighboring tissues, and they may lead to endocrine dysfunction or cranial nerve deficiencies. Therapeutic options comprise surgery, radiation, and pharmacotherapy. The extent of surgical resection is often limited in invasive or recurrent PAs. Radiation therapy, which is usually applied with remnants or recurrence of PAs at an inoperable site, may affect neighboring tissues and induce tumors. Pharmacotherapy is useful only in certain PAs, depending on the hormones and receptors expressed in the tumor cells [1].

In 2011, McCormack et al. [2] published a careful analysis of reports on the potential usefulness of temozolomide (TMZ) in aggressive PAs. In 2018, the European Society of Endocrinology has recommended TMZ as first-line chemotherapy in cases of aggressive PAs that are refractory to standard treatment [3]. However, a positive treatment effect of TMZ was only observed in 47 percent of cases [3]. Other than that, there is no widely recommended or evidence-based chemotherapeutic option to treat aggressive PAs.

Abbreviations
ADAM, a disintegrin and metalloproteinase; ctrl, control; DAPI, 4’,6-diamidino-2-phenylindole; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IC, inhibitory concentration; min, minute; MMP, matrix metalloproteinase; PA, pituitary adenoma; qPCR, quantitative real-time-polymerase chain reaction; RIPA, radioimmunoprecipitation assay; rpm, revolutions per minute; SEM, standard error of the mean; SERM, selective estrogen receptor modulator; scr, scramble; siRNA, small interfering ribonucleic acid; TGF, transforming growth factor; TMZ, temozolomide.
Several in vitro studies suggest antitumorigenic effects of selective estrogen receptor modulators (SERMs) like resveratrol [4–6] or clinically applicable drugs like bazedoxifene, clomiphene, and raloxifene [7] on rodent PA cells. In acromegalic men, the SERM raloxifene has been shown to reduce insulin-like growth factor 1 levels [8]. There are indications that SERMs have an impact on cell-extracellular matrix interaction which may subsequently affect invasiveness, for example, in breast cancer cells: Tamoxifen, a SERM, has been shown to reduce extracellular transforming growth factor-beta 1 (TGF-beta) expression, while inhibition of matrix metalloproteinase (MMP) activity restored TGF-beta levels in estrogen receptor-positive breast cancer cells [9]. Reduced disease-free survival time has been reported in patients with estrogen receptor-negative and MMP-9-positive breast cancer [10]. Induction of MMP-9 expression by laminin in a human cervical cancer cell line [11] and upregulation of MMP-9 as well as coordinated expression of MMP-2 and MMP-14 by fibronectin in a human T lymphocyte cell line [12] have been demonstrated. MMP-14 and a disintegrin and metalloproteinase-12 (ADAM12) levels in human PA tissue samples are correlated with cavernous sinus invasion [13].

Here, we aim to investigate the impact of three clinically applicable SERMs, namely bazedoxifene, clomiphene, and raloxifene, on invasiveness in vitro and correlate their effects with gene and protein expression levels of MMP-14 and ADAM12 in two murine PA cell lines mainly expressing estrogen receptor alpha (ER-α, 7), AtT-20 and TtT/GF. Since to date, no human PA cells are available, these cell lines might serve as a model for human studies.

Materials and methods

Reagents

Selective estrogen receptor modulators (bazedoxifene, clomiphene, and raloxifene) were purchased from Biomol (Hamburg, Germany). They were dissolved in DMSO (Sigma, St. Louis, MO, USA). Batimastat was obtained from Tocris Bioscience (Bio-Techne, Wiesbaden, Germany).

Cells and cultivation

We obtained AtT-20 cells from the American Type Culture Collection (ATCC, Wesel, Germany). TtT/GF cells were kindly provided by the former laboratory of Dr. med. habil. Nicolai Savaskan at Erlangen University, Germany. Cells were grown in phenol red-free Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Gibco), 0.1 mg·mL⁻¹ penicillin/streptomycin (Biochrom, Berlin, Germany), sodium pyruvate (1 mm; Biochrom), and nonessential amino acids (1x; Biochrom). Cells were cultivated under 5% CO₂ at 37 °C.

Viability assay

One hundred microlitre medium per well containing 5000 cells per well was placed in 96-well plates for 24 h. Thereafter, SERMs were added at the indicated concentrations. After another 48 h, 50 μL CellTiter-Glo® (Promega, Mannheim, Germany) per well were added. The plate was then vigorously shaken for 10 min and incubated for 20 min at room temperature in the dark. A FLUOstar OPTIMA Microplate Reader (BMG Labtech, Offenburg, Germany) was employed to detect luminescence. All experiments on viability were conducted in triplicates.

Invasion assay

Eight-micrometre transwell inserts (Greiner Bio-One, Frickenhausen, Germany) were used with 24-well plates. The inserts were coated on the upper side with 50 μL Matrigel (Corning® Matrigel® Matrix, Basement Membrane Matrix Growth Factor Reduced, Corning Incorporated, Corning, NY, USA). After 1 h at 37 °C under 5% CO₂, the Matrigel was solid. The transwell insert was then turned upside down, and 25,000 TtT/GF cells per well resp. 50,000 AtT-20 cells per well in 50 μL medium containing 0.5% FBS were seeded on the other side. After 4 h allowed for adherence, the transwell insert was turned upside up again. To build an FBS gradient, 250 μL medium containing 10% FBS was applied on top of each Matrigel layer, while 750 μL medium containing 0.5% FBS was placed in each of the 24 wells. After 24 h allowed for invasion, cells were fixed with 4% paraformaldehyde (Sigma), treated with 0.3% octoxynol-9 ( Triton™ X-100 buffer; Sigma), and stained with 4’,6-diamidin-2-phenylindole (DAPI; Sigma). Cells were counted in five randomly chosen viewing fields [respectively 10 randomly chosen viewing fields with the small interfering ribonucleic acid (siRNA) experiments]. The percentage of cells that had invaded into the Matrigel was determined.

Quantitative real time-polymerase chain reaction (qPCR)

Cells were lysated in 1 mL Qiazol (Qiagen, Hilden, Germany). After resuspension, 200 μL chloroform was added. After mixing and incubation at room temperature for 3 min, cells were centrifuged (15 600 g, 15 min, 4 °C). The upper aqueous phase was transferred into a new 1.5-mL
Antibodies, protein extraction, and western blot

Rabbit polyclonal anti-MMP-14 and anti-angiogenic fibrillar acidic protein antibodies were purchased from Abcam (Cambridge, UK). Rabbit polyclonal anti-ADAM12 antibody was obtained from Proteintech (Rosemont, IL, USA). Anti-GAPDH (Abcam) and anti-β-tubulin (Novus Biologicals, Littleton, CO, USA) served as loading controls, horse-radish peroxidase-conjugated donkey anti-rabbit immunoglobulin G from Abcam was used as secondary antibody.

Total protein was extracted from the cells (AtT20: 5 × 10^5, Ti/TiGF: 2 × 10^5) with radioimmunoprecipitation assay (RIPA) buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4, Sigma); 150 mM NaCl; 1% nondenaturing sodium dodecyl sulfate (NP-40); 1 mM phenylmethylsulfonyl fluoride (Sigma); 0.5% sodium deoxycholate; 0.1% SDS (SERVA, Heidelberg, Germany); 10 mM phenanthroline; 10 mM ethylenediaminetetraacetic acid (EDTA)] that contained phosphatase inhibitors ( Pierce™ Phosphatase Inhibitor Mini Tablets; Thermo Fisher Scientific), and protease inhibitors ( Pierce™ Protease Inhibitor Mini Tablets, EDTA free; Thermo Fisher Scientific). In a 6-well plate, 200 µL RIPA buffer per well was added to the cells and incubated for 15 min on ice. Shearing of the DNA was accomplished by using a 25-G needle to resuspend the samples, which were subsequently incubated for another 30 min on ice. The lysates were then centrifuged (14 400 g, 15 min, 4 °C), and the resulting supernatant, that is, the total cellular protein, was stored at −80 °C. For 5 min, lysates were boiled in Laemmli buffer (60 mM Tris/HCl, pH = 6.8; 2% SDS; 10% glycerol; 5% β-mercaptoethanol; 0.01% bromophenol blue). A bicinchoninic acid assay (Thermo Fisher Scientific) was used to determine protein concentrations.

Proteins from equal amounts of lysate were separated by SDS/PAGE. Proteins were then transferred onto nitrocellulose membranes. To block any unspecific binding, membranes were immersed and gently shaken in 5% nonfat, dried milk in Tris-buffered saline Tween-20 (TBST; 50 mM Tris, pH = 7.5; 150 mM NaCl; 0.1% Tween-20 [CARL ROTH, Karlsruhe, Germany]) for 1 h, after which they were incubated with primary antibodies at 4 °C overnight. After three washing steps with TBST, blots were incubated with the secondary antibody for 1 h. After another washing step, signals were detected with Western Bright Chemiluminescence Substrate Sirius (Biozym Scientific, Hessisch Oldendorf, Germany) and chemiluminescence was determined using a Chemostar Imager (Intas, Göttingen, Germany) and IMAGEJ (National Institutes of Health, Bethesda, MD, USA) for quantification. Several exposure times were compared to confirm linearity of the signals.

siRNA transfection

FlexiTube Gene Solution siRNA for mouse ADAM12, mouse MMP-14, and AllStars-negative control siRNA (Qiagen) was applied in AtT-20 and Ti/Ti/GF cells. Transfection was carried out using HiPerFect reagent (Qiagen) according to the manufacturer’s protocol with 5 nm siRNA applied. The resulting silencing of proteins was confirmed by western blotting as described above. Invasion rates were established according to the invasion assay protocol given above.

Statistics

GraphPad Prism version 8.0.1 (GraphPad Software, San Diego, CA, USA) was used to fit the dose–response curves using nonlinear regression, to estimate the IC_{25} and IC_{50} values, and to calculate protein band densities as assessed with IMAGEJ Fiji (https://imagej.net), page visited on August 21, 2020) on a Mac OS X (Apple Inc., Cupertino, CA, USA).

For the invasion assay and the qPCR, statistical analysis was conducted and figures were created with R Studio version 1.1.383 (R Studio, Boston, MA, USA, https://rstudio.com, page visited on May 21, 2020) running R version 4.0.0 ‘Arbor Day’ (The R Foundation, Vienna, Austria, https://www.r-project.org, page visited on May 21, 2020) on a Mac OS X (Apple Inc.).

If not indicated otherwise, data are presented as mean values ± standard error of the mean (SEM). t served as statistical test, and P values of < 0.05 were considered statistically significant. To assess differences in multiple group
means, ANOVA and t testing with a correction for type I error were applied.

**Results**

At first, we determined dose–response curves for the three SERMs bazedoxifene, clomiphene, and raloxifene in AtT-20 and TtT/GF cells. According to the 50% inhibitory concentration (IC50) values, we found that in AtT-20 cells, bazedoxifene exerted the most pronounced impact on viability, while in TtT/GF cells clomiphene had the highest impact on viability which was comparable to that of bazedoxifene in the same cells (Fig. 1A,B, Table 1).

**SERMs decrease invasiveness in murine PA cells**

Invasion assays using Matrigel were performed with AtT-20 and TtT/GF cells (Fig. 2A). We observed a significant impact on invasiveness after treatment of AtT-20 cells with clomiphene ($P = 0.027$) and raloxifene ($P = 0.009$) and after treatment of TtT/GF cells with clomiphene ($P = 0.022$) and bazedoxifene ($P = 0.002$) at the respective IC25 (Fig. 2B,C). The effects of the three SERMs at IC25 were compared to control media and to the effect of batimastat, a broad-range MMP inhibitor, which also exerted a significant effect on invasiveness in both cell lines ($P < 0.01$, Fig. 2B,C).

---

**Fig. 1.** Dose–response curves for SERMs bazedoxifene, clomiphene, and raloxifene in PA cell lines AtT-20 (A) and TtT/GF (B). Values are indicated as mean ± SEM. ctrl, control.
Table 1. Summary of IC\textsubscript{25} and IC\textsubscript{50} values for different anti-estrogens (in µM) for each cell line as determined by dose–response curves. Concentrations as indicated in this table were used for all other experiments in this study.

|               | Bazedoxifene | Bazedoxifene | Clomiphene | Clomiphene | Raloxifene | Raloxifene |
|---------------|--------------|--------------|------------|------------|------------|------------|
|               | IC\textsubscript{25} | IC\textsubscript{50} | IC\textsubscript{25} | IC\textsubscript{50} | IC\textsubscript{25} | IC\textsubscript{50} |
| AtT-20        | 0.61         | 0.88         | 0.87       | 1.21       | 1.10       | 2.27       |
| TtT/GF        | 2.34         | 3.54         | 2.67       | 3.51       | 9.37       | 11.94      |

Fig. 2. Selective estrogen receptor modulators reduce invasiveness in PA cell lines AtT-20 (B) and TtT/GF (C). (A) Representative images of AtT20 (upper panel) and TtT/GF (lower panel) cells stained with DAPI. Note that cell lines were treated with 25% inhibitory concentrations (IC\textsubscript{25}) of SERMs bazedoxifene, clomiphene, and raloxifene as indicated in Table 1. Scale bar in (A), for all images, 50 μm. Batimastat, a broad-range MMP inhibitor, served as positive control. With bazedoxifene in TtT/GF cells, the outlier (o) was excluded from the statistical analysis. Values are given as median, first quartile, and third quartile. Values are obtained from three independent experiments performed in triplicates. t\textsubscript{s} served as statistical test. *Statistically significant difference as compared to control.
SERM treatment decreases MMP-14 and ADAM12 mRNA expression in murine PA cells

To analyze those metalloproteases affecting invasiveness of PA cells, we determined the mean qPCR cycle numbers representing absolute values of MMP-1, MMP-9, MMP-14, ADAM8, and ADAM12 gene expression in untreated AtT-20 and TtT/GF cells. Whereas MMP-1, MMP-9, and ADAM8 showed low expression levels, we detected high gene expression levels of MMP-14 in TtT/GF cells and of ADAM12 in both cell lines (Fig. 3). These results prompted us to particularly investigate the potential impact of SERMs on MMP-14 and ADAM12 gene expression in AtT-20 and TtT/GF cells.

We could demonstrate a significant impact of bazedoxifene ($P < 0.01$), clomiphene ($P < 0.01$), and raloxifene ($P < 0.01$) on mRNA gene expression of ADAM12 in AtT-20 cells. We further observed a significant impact of bazedoxifene ($P < 0.01$) and raloxifene ($P = 0.01$) on the mRNA gene expression of MMP-14 in TtT/GF cells, as well as a significant impact of bazedoxifene ($P < 0.001$) and raloxifene ($P < 0.001$) on the mRNA gene expression of ADAM12 in TtT/GF cells, each as compared to blank controls (Fig. 4A,C,D). With or without SERMs, a relevant gene expression of MMP-14 in AtT-20 cells was not detected (Fig. 3, data after SERM treatment not shown). In either cell line, the gene expression levels of ADAM-related Basigin were not significantly downregulated by SERM treatment (Fig. 4B,E).

Gene silencing of ADAM12 and MMP-14 decreases invasiveness of murine PA cells

To evaluate the role of ADAM12 and MMP-14 in PA cell invasion, we analyzed the impact of ADAM12 and MMP-14 gene silencing on invasiveness in AtT-20 and TtT/GF cells. Transfection of AtT-20 and TtT/GF cells with ADAM12 and MMP-14 siRNA resulted in a significantly reduced protein expression of ADAM12 in both cell lines (Fig. 5A,C) and of MMP-14 in TtT/GF cells (Fig. 5C). These cells were subjected to invasion assays and showed significantly decreased invasion rates of AtT-20 cells after ADAM12 silencing ($P = 0.013$, Fig. 5B), of TtT/GF cells after ADAM12 silencing ($P < 0.001$, Fig. 5D) and of TtT/GF cells after MMP-14 silencing ($P = 0.011$, Fig. 5D).

SERM treatment decreases MMP-14 and ADAM12 protein levels in murine PA cells

In AtT-20 cells, treatment with bazedoxifene, clomiphene, and raloxifene at IC$_{50}$ each obviously decreased ADAM12 protein expression (Fig. 6A) as compared to DMSO and blank controls. In this cell line, an impact of the three drugs on MMP-14 protein expression was not found according to the western blot (Fig. 6C) which, in AtT-20 cells, hardly detected any MMP-14 protein at all—in accordance with the qPCR results (Fig. 3).

In TtT/GF cells, treatment with bazedoxifene, clomiphene, and raloxifene at IC$_{50}$ each obviously decreased MMP-14 protein expression as compared to the blank control (Fig. 6D). In the same cells, treatment with bazedoxifene and raloxifene at IC$_{50}$ also obviously decreased MMP-14 protein expression as compared to the DMSO control, whereas treatment with clomiphene at IC$_{50}$ exerted only a moderate effect as compared to the DMSO control. A significant impact on ADAM12 protein expression in TtT/GF cells was only found for raloxifene according to the western blot (Fig. 6B).

Discussion

The impact of SERMs on viability and invasion in rodent PA cells and the correlation of MMP-14 and ADAM12 expression with invasiveness in human PAs have been demonstrated previously [4–7,13]. However, this is to our knowledge the first study that connects SERMs with reduced expression levels of MMP-14.
and ADAM12, and reduced invasiveness in PA cell lines. Our findings demonstrate the potential of these drugs as inhibitors of invasion in PA cells which could become highly relevant for potential clinical applications.

### Fig. 4
Quantitative real-time-polymerase chain reaction to determine mRNA levels of ADAM12 in AtT-20 (A), of Basigin in AtT-20 cells (B), of ADAM12 in TtT/GF cells (C), of MMP-14 in TtT/GF cells (D), and of basigin in TtT/GF cells (E) in response to SERM treatment. For each SERM (raloxifene, bazedoxifene, and clomiphene), 50% inhibitory concentrations (IC50) as indicated in Table 1 were used to treat cells for 72 h. Quantitative PCR was performed in three independent experiments in triplicates. Values are given as median, first quartile, and third quartile. t served as statistical test. *Statistically significant difference as compared to control.

### Fig. 5
Transfection of AtT-20 (A, B) and TtT/GF (C, D) cells with siRNA silencing ADAM12 and MMP-14 genes and their effect on invasion. Western blots for the respective proteins in AtT-20 (A) and TtT/GF (C) cells; scramble ('scr') siRNA served as transfection and tubulin as loading controls. Invasion rates after selective silencing of ADAM12 and MMP-14 genes as compared to scramble siRNA in AtT-20 (B) and TtT/GF cells (D) were calculated. Values are obtained from three independent experiments in triplicates and are indicated as median, first quartile, and third quartile. t served as statistical test. *Statistically significant difference as compared to control (Scramble).
A significant impact on invasion was observed after treatment of AtT-20 cells with clomiphene and raloxifene and after treatment of TtT/GF cells with bazedoxifene and clomiphene. However, all the tested drugs moderated the invasive potential in both cell lines at least to some extent at IC25. These observations are somewhat different from those reported in [7], which may be explained by differences in incubation times and cell passages between studies.

ADAM12 and MMP-14 have been found to be related to cavernous sinus invasion in human PA tissue samples [13] as well as to growth in other tumors, for example, breast cancer [14]. We found the gene expression levels of ADAM12 in AtT-20 and TtT/GF cells and of MMP-14 in TtT/GF cells to be significantly downregulated after treatment with bazedoxifene, clomiphene, and raloxifene. Furthermore, we found that bazedoxifene and raloxifene decreased protein expression of MMP-14 in TtT/GF cells, and all three drugs decreased protein expression of ADAM12 in AtT-20 cells whereas only raloxifene significantly downregulated protein expression of ADAM12 in TtT/GF cells.

There are several limitations associated with this study. The absence of MMP-14 gene expression in AtT-20 cells as opposed to TtT/GF cells and the difference in ADAM12 protein expression in AtT-20 cells as opposed to TtT/GF cells indicate that there are distinct mechanisms of invasion involved in each of the cell lines, deserving future elucidation, including...
investigation of the potential impact of SERMs on other invasion-related proteases. Another limitation is that it remains difficult to extrapolate from findings in rodent PA cells in vitro to potential applications in humans, since several challenges have to be overcome: In different PA cell lines from the same species, the same treatment may lead to distinct responses, as we have observed here. One may expect such differences to be similar or even more pronounced in other species. Furthermore, cultivation of human PA cells is still a major obstacle. Last but not least, apart from intravenously administered clomiphene, the concentrations of the drugs tested in this study are much higher than plasma concentrations usually achievable in humans [15–17] (Table S1).

We find it nonetheless very encouraging to see that in murine PA cells, SERMs downregulate two proteases that apparently play key roles in cavernous sinus invasion in human PAs [13].

Conclusion
Selective estrogen receptor modulators decrease invasiveness of murine PA cell lines AtT-20 and TtT/GF and regulate expression levels of MMP-14 and ADAM12, two important invasion-related proteins in murine PA cells as well as in human PA tissue samples. Our findings support the view that SERMs might become a potential salvage therapy for aggressive PAs.

Acknowledgements
We thank Kai Zhao for helpful advice with the western blots. This study did not receive any external funding. Open access funding enabled and organized by ProjektDEAL.

Conflict of interest
The authors declare no conflict of interest.

Data accessibility
All data will be available from the corresponding author upon reasonable request.

Author contributions
ZZ conducted experiments and statistical analysis; JWB supervised the study and drafted the manuscript; JB conducted experiments and read the manuscript; TL supervised the study and read the manuscript; CN supervised the study, provided laboratory facilities and staff, and read the manuscript; BV conceived the project, supervised the study, conducted statistical analysis, and drafted the manuscript.

References
1 Fahrbusch R and Buchfelder M (2011) Pituitary surgery. In The Pituitary, 3rd edn (Melmed S, ed.), pp. 703–719. Academic Press, London.
2 McCormack AI, Wass JA and Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 41, 1133–1148.
3 Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM and European Society of Endocrinology (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178, G1–G24.
4 Wang C, Hu ZQ, Chu M, Wang Z, Zhang W, Wang L, Li C and Wang J (2012) Resveratrol inhibited GH3 cell growth and increased prolactin level via estrogen receptors. Clin Neurol Neurosurg 114, 241–248.
5 Voellger B, Kirches E, Wilisch-Neumann A, Weise A, Tapia-Perez JH, Rupa R, Mawrin C and Firsching R (2013) Resveratrol decreases B-cell lymphoma-2 expression and viability in GH3 pituitary adenoma cells of the rat. OncoTargets Ther 6, 1269–1276.
6 Voellger B, Waldt N, Rupa R, Kirches E, Melhem O, Ochel H-J, Mawrin C and Firsching R (2018) Combined effects of resveratrol and radiation in GH3 and TtT/GF pituitary adenoma cells. J NeuroOncol 139, 573–582.
7 Hannen R, Steffani M, Voellger B, Carl B, Wang J, Bartsch JW and Nimsky C (2019) Effects of anti-estrogens on cell invasion and survival in pituitary adenoma cells: a systematic study. J Steroid Biochem Mol Biol 187, 88–96.
8 Dimaraki EV, Symons KV and Baran AL (2004) Raloxifene decreases serum IGF-1 in male patients with active acromegaly. Eur J Endocrinol 150, 481–487.
9 Nilsson UW, Jönsson JA and Dabrosin C (2009) Tamoxifen decreases extracellular TGF-beta1 secreted from breast cancer cells—a post-translational regulation involving matrix metalloproteinase activity. Exp Cell Res 315, 1–9.
10 Rahko E, Jukkola A, Melkko J, Paavo P, Bloigu R, Talvensaari-Mattila A and Turpeenniemi-Hujanen T (2004) Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy. Anticancer Res 24, 4247–4253.
11 Maity G, Sen T and Chatterjee A (2011) Laminin induces matrix metalloproteinase-9 expression and
activation in human cervical cancer cell line (SiHa). J Cancer Res Clin Oncol 137, 347–357.

12 Esparza J, Vilardell C, Calvo J, Juan M, Vives J, Urbano-Márquez A, Yagüe J and Cid MC (1999) Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood 94, 2754–2766.

13 Wang J, Voellger B, Benzel J, Schlomann U, Nimsky C, Bartsch JW and Carl B (2016) Metalloproteinases ADAM12 and MMP-14 are associated with cavernous sinus invasion in pituitary adenomas. Int J Cancer 139, 1327–1339.

14 Albrechtsen R, Kveiborg M, Stautz D, Vikesa J, Noer JB, Kotzsh A, Nielsen FC, Wewer UM and Frohlich C (2013) ADAM12 redistributes and activates MMP-14, resulting in gelatin degradation, reduced apoptosis and increased tumor growth. J Cell Sci 126, 4707–4720.

15 Chandrasekaran A, McKeand WE and Sullivan P (2009) Metabolic disposition of [14C]Bazedoxifene in healthy postmenopausal women. Drug Metab Dispos 37, 1219–1225.

16 Szutu M, Morgan DJ and McLeish M (1989) Pharmacokinetics of intravenous clomiphene isomers. Br J Clin Pharmacol 27, 639–640.

17 Czock D, Keller F, Heringa M and Rasche FM (2005) Raloxifene pharmacokinetics in males with normal and impaired renal function. Br J Clin Pharmacol 59, 479–482.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Molecular characteristics of the three selective estrogen receptor modulators (SERMs) that were used to treat AtT-20 and TtT/GF cells in our study. aas retrieved from http://www.drugbank.ca on May 21, 2020; bsee reference number 15; csee reference number 16; dsee reference number 17; for the respective inhibitory concentration (IC) values, please refer to table 1.